keyword
MENU ▼
Read by QxMD icon Read
search

Rifaximin

keyword
https://www.readbyqxmd.com/read/29235218/efficacy-and-safety-of-rifaximin-in-japanese-patients-with-hepatic-encephalopathy-a-phase-2-3-multicenter-randomized-evaluator-blinded-active-controlled-trial-and-a-phase-3-multicenter-open-trial
#1
Kazuyuki Suzuki, Ryujin Endo, Yasuhiro Takikawa, Fuminori Moriyasu, Yutaka Aoyagi, Hisataka Moriwaki, Shuji Terai, Isao Sakaida, Yoshiyuki Sakai, Shuhei Nishiguchi, Toru Ishikawa, Hitoshi Takagi, Atsushi Naganuma, Takuya Genda, Takafumi Ichida, Koichi Takaguchi, Katsuhiko Miyazawa, Kiwamu Okita
AIM: The efficacy and safety of rifaximin in the treatment of hepatic encephalopathy (HE) are widely known, but they have not been confirmed in Japanese patients with HE. Thus, two prospective, randomized studies (phase 2/3 study and phase 3 study) were conducted. METHODS: Subjects with grade I or II HE and hyperammonemia were enrolled. The phase 2/3 study, which was a randomized, evaluator-blinded, active-comparator, parallel-group study, was conducted at 37 institutions in Japan...
December 13, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29204952/-therapeutic-modulation-of-intestinal-microbiota-in-irritable-bowel-syndrome-from-probiotics-to-fecal-microbiota-therapy
#2
P C Konturek, Yurdagül Zopf
BACKGROUND: An abnormal intestinal microbiota (dysbiosis) plays a central role in the pathogenesis of the irritable bowel syndrome. METHOD: An overview of four current options for the treatment of irritable bowel syndrome, which are characterized by modulation of intestinal microbiota, is given. RESULTS AND CONCLUSIONS: Probiotics have very different effects on the individual symptoms of the irritable bowel. The choice of the appropriate preparation should therefore be based on the clinical symptomatology...
December 2017: MMW Fortschritte der Medizin
https://www.readbyqxmd.com/read/29201772/managing-encephalopathy-in-the-outpatient-setting
#3
REVIEW
Tarana Gupta, Sahaj Rathi, Radha K Dhiman
In cirrhosis of liver, hepatic encephalopathy (HE) has an important impact on health-related quality of life. It is important to define whether HE is episodic, recurrent, or persistent; types A, B, or C; overt HE or covert HE; and spontaneous or precipitated. The overt HE is clinically evident and needs hospitalization. Nonabsorbable disaccharides, rifaximin, and probiotics are proven to be useful in the treatment of overt HE. Covert HE includes both minimal HE and grade I HE. It is not apparent on routine clinical examination...
January 2017: Euroasian journal of hepato-gastroenterology
https://www.readbyqxmd.com/read/29201193/effect-of-different-treatments-and-alcohol-addiction-on-gut-microbiota-in-minimal-hepatic-encephalopathy-patients
#4
Zan Zuo, Hong Fan, Xiao-Dan Tang, Yan-Min Chen, Lin-Ting Xun, Yan Li, Zheng-Ji Song, Hui-Qiong Zhai
Minimal hepatic encephalopathy (MHE) is caused by dysbiosis of gut microbiota, particularly the ammonia-producing bacteria. Given the efficacy of certain treatments on MHE and the connection between alcoholism and MHE, a thorough understanding of how these strategies affect the gut microbiota in patients (alcoholic or non-alcoholic) will facilitate the assessment of their efficacy in the reshaping of gut microbiota. In the present study, a metagenomics approach was adopted to reveal alterations in gut microbiota of 14 MHE patients following treatment with rifaximin alone or rifaximin plus probiotics...
November 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29172123/existing-and-emerging-therapies-for-managing-constipation-and-diarrhea
#5
REVIEW
Adil E Bharucha, Mira M Wouters, Jan Tack
Functional bowel disorders (i.e., constipation and diarrhea) are characterized by abdominal pain, bloating, distention, and/or bowel habit abnormalities in the absence of obvious anatomic or physiologic abnormalities on routine diagnostic tests. These symptoms are attributable to gastrointestinal sensorimotor dysfunctions resulting from peripheral and/or central mechanisms. Available drugs target the underlying bowel disturbance (i.e., constipation, diarrhea, or both), supplemented when necessary by management of pain...
November 21, 2017: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29171503/-prevention-and-treatment-of-hepatic-encephalopathy
#6
Yu P Sivolap
Hepatic encephalopathy is a common neuropsychiatric complication of serious liver diseases and serves as a marker for worsening of their course and increasing the risk of death. The principal pathogenesis factors of hepatic encephalopathy is the excessive formation of ammonia and its accumulation by astrocytes. A key role in the prevention and treatment of hepatic encephalopathy is played by drugs that prevent hyperammonemia and promote the removal of ammonia from the body, namely lactulose, rifaximin and L-ornithine-L-aspartate...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29161793/effect-of-rifaximin-on-hepatic-fibrosis-in-bile-duct-ligated-rat-model
#7
Seung Kak Shin, Oh Sang Kwon, Jong Joon Lee, Yeon Ho Park, Cheol Soo Choi, Sung Hwan Jeong, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim
Background/Aims: The translocation of bacteria and their lipopolysaccharides from the gut can promote fibrosis in cirrhotic patients. The aim of this study was to investigate the effects of rifaximin on hepatic fibrosis in a bile duct-ligated rat model. Methods: The bile duct ligation (BDL) was carried out for eight days (acute injury model: sham-operated rats [G1], BDL rats [G2], and BDL rats treated with rifaximin [G3]) or 22 days (chronic injury model: sham-operated rats [G4], BDL rats [G5], and BDL rats treated with rifaximin [G6])...
November 25, 2017: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://www.readbyqxmd.com/read/29150304/are-the-estrogenic-hormonal-effects-of-environmental-toxins-affecting-small-intestinal-bacterial-and-microfilaria-overgrowth
#8
Edward Lichten
The important role of microfilaria (worms) in human and animal disease remains an area of key disagreement between the naturopathic and allopathic physicians. While microfilaria infections are rampart in undeveloped countries, they rarely rise to identification as a cause of disease in Western countries. New research studies in the diagnosis and treatment of SIBO (Small Intestinal Bacterial Overgrowth) and (IBD) Inflammatory Bowel Diseases of ulcerative colitis, Crohn's Disease and microcytic colitis may make both sides equally correct...
November 2017: Medical Hypotheses
https://www.readbyqxmd.com/read/29145631/rifaximin-fails-to-prevent-campylobacteriosis-in-the-human-challenge-model-a-randomized-double-blind-placebo-controlled-trial
#9
Joanna E Rimmer, Clayton Harro, David A Sack, Kawsar R Talaat, Ramiro L Gutierrez, Barbara DeNearing, Jessica Brubaker, Renee M Laird, Frédéric Poly, Alexander C Maue, Kayla Jaep, Ashley Alcala, Yelizaveta Mochalova, Christina L Gariepy, Subhra Chakraborty, Patricia Guerry, David R Tribble, Chad K Porter, Mark S Riddle
Background: Campylobacter species are a leading cause of diarrheal disease globally with significant morbidity. Primary prevention efforts have yielded limited results. Rifaximin chemoprophylaxis decreases travelers' diarrhea rates and may be suitable for high risk persons. We assessed the efficacy of rifaximin in the controlled human infection model (CHIM) for Campylobacter jejuni. Methods: Twenty-eight subjects were admitted to an inpatient facility and randomized to a twice daily dose of 550 mg rifaximin or placebo...
November 14, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29130574/drug-interactions-between-rifamycin-antibiotics-and-hormonal-contraception-a-systematic-review
#10
Katharine B Simmons, Lisa B Haddad, Kavita Nanda, Kathryn M Curtis
BACKGROUND: Rifamycin antibiotics are commonly used for treatment of tuberculosis, but may reduce effectiveness of hormonal contraception (HC). OBJECTIVES: To determine whether interactions between rifamycins and HC result in decreased effectiveness or increased toxicity of either therapy. SEARCH STRATEGY: We searched MEDLINE, Embase, Cochrane and clinicaltrials. gov through May, 2017. SELECTION CRITERIA: We included trials, cohort, and case-control studies addressing pregnancy rates, pharmacodynamics, or pharmacokinetic (PK) outcomes when HC and rifamycins were administered together versus apart...
November 12, 2017: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/29118468/the-intricate-link-among-gut-immunological-niche-microbiota-and-xenobiotics-in-intestinal-pathology
#11
REVIEW
Danilo Pagliari, Giovanni Gambassi, Ciriaco A Piccirillo, Rossella Cianci
Inflammatory bowel diseases (IBDs) are diseases characterized by various degrees of inflammation involving the gastrointestinal tract. Ulcerative colitis and Crohn's disease are characterized by a dysregulated immune response leading to structural gut alterations in genetically predisposed individuals. Diverticular disease is characterized by abnormal immune response to normal gut microbiota. IBDs are linked to a lack of physiological tolerance of the mucosal immune system to resident gut microbiota and pathogens...
2017: Mediators of Inflammation
https://www.readbyqxmd.com/read/29099760/symptom-severity-following-rifaximin-and-the-probiotic-vsl-3-in-patients-with-chronic-pelvic-pain-syndrome-due-to-inflammatory-prostatitis-plus-irritable-bowel-syndrome
#12
Enzo Vicari, Michele Salemi, Giuseppe Sidoti, Mariano Malaguarnera, Roberto Castiglione
This study investigated the effects of long-term treatment with rifaximin and the probiotic VSL#3 on uro-genital and gastrointestinal symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) plus diarrhoea-predominant irritable bowel syndrome (D-IBS) compared with patients with D-IBS alone. Eighty-five patients with CP/CPPS (45 with subtype IIIa and 40 with IIIb) plus D-IBS according to the Rome III criteria and an aged-matched control-group of patients with D-IBS alone (n = 75) received rifaximin and VSL#3...
November 3, 2017: Nutrients
https://www.readbyqxmd.com/read/29084080/metronidazole-or-rifaximin-for-treatment-of-clostridium-difficile-in-pediatric-patients-with-inflammatory-bowel-disease-a-randomized-clinical-trial
#13
Agnieszka Gawronska, Marcin Banasiuk, Dominika Lachowicz, Hanna Pituch, Piotr Albrecht, Aleksandra Banaszkiewicz
BACKGROUND: Interestingly, Clostridium difficile infection (CDI) worsens the course of inflammatory bowel disease (IBD); however, there is a paucity of data regarding the treatment of CDI in this group of patients. METHODS: This was a prospective, single-blind trial. Children with flare of IBD and CDI were randomly assigned to receive metronidazole or rifaximin orally for 14 days. CDI was diagnosed based on a positive well-type enzyme immunoassay (EIA) toxins A/B stool test for C...
December 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29082939/rifaximin-treatment-for-encephalopathy-reduces-hospital-resource-use-real-world-data-don-t-fail-to-impress
#14
COMMENT
John D Ryan, Emmanuel A Tsochatzis
No abstract text is available yet for this article.
October 2017: Frontline Gastroenterology
https://www.readbyqxmd.com/read/29069372/breakthrough-clostridium-difficile-infection-in-cirrhotic-patients-receiving-rifaximin
#15
E Reigadas, L Alcalá, J Gómez, M Marín, A Martin, R Onori, P Muñoz, E Bouza
Background: Patients with cirrhosis are at high risk of Clostridium difficile infection (CDI). Rifaximin is commonly used in cirrhotic patients as prophylaxis for hepatic encephalopathy (HE). Several studies have demonstrated the efficacy of rifaximin in the treatment of CDI; however, resistance to rifaximin has also been reported. Few studies have assessed the risk of developing CDI in cirrhotic patients receiving rifaximin. Our objective was to assess the incidence and characteristics of CDI in cirrhotic patients, especially in those who received rifaximin...
October 23, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29068235/comment-rifampin-resistant-staphylococcus-aureus-bacteremia-in-a-patient-on-chronic-rifaximin
#16
Herbert L DuPont, Jasmohan S Bajaj
No abstract text is available yet for this article.
October 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29067149/the-impact-of-rifaximin-%C3%AE-on-the-hospital-resource-use-associated-with-the-management-of-patients-with-hepatic-encephalopathy-a-retrospective-observational-study-impress
#17
Mark Hudson, Amr Radwan, Paola Di Maggio, Riccardo Cipelli, Stephen D Ryder, John F Dillon, William Jonathan Cash, Robert T Przemioslo, Mark Wright, Debbie L Shawcross, Rajiv Jalan, Sushma Saksena, Michael Allison, Paul Richardson, Elizabeth Farrington, Richard J Aspinall
OBJECTIVE: To compare all-cause and liver-related hospital resource use in the 6 and 12 months pre-rifaximin-α and post-rifaximin-α initiation in UK patients with hepatic encephalopathy (HE). DESIGN: A UK multicentre, retrospective, observational study. Patients' medical records were reviewed for demographics, clinical outcomes and adverse events (AEs) to rifaximin-α. Details of hospital admissions/attendances in the 6 and 12 months pre-rifaximin-α and post-rifaximin-α initiation were extracted from hospital electronic databases...
October 2017: Frontline Gastroenterology
https://www.readbyqxmd.com/read/29052858/editorial-rifaximin-in-cirrhosis-is-it-what-we-ve-been-waiting-for
#18
EDITORIAL
J Huang
No abstract text is available yet for this article.
November 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29052857/editorial-rifaximin-in-cirrhosis-is-this-what-we-ve-been-waiting-for-authors-reply
#19
EDITORIAL
S H Kang, Y B Lee, J-H Lee
No abstract text is available yet for this article.
November 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29029033/trial-evaluating-ambulatory-therapy-of-travelers-diarrhea-treat-td-study-a-randomized-controlled-trial-comparing-3-single-dose-antibiotic-regimens-with-loperamide
#20
Mark S Riddle, Patrick Connor, Jamie Fraser, Chad K Porter, Brett Swierczewski, Emma J Hutley, Brook Danboise, Mark P Simons, Christine Hulseberg, Tahaniyat Lalani, Ramiro L Gutierrez, David R Tribble
Background: Recommended treatment for travelers' diarrhea includes the combination of an antibiotic, usually a fluoroquinolone or azithromycin, and loperamide for rapid resolution of symptoms. However, adverse events, postdose nausea with high-dose azithromycin, effectiveness of single-dose rifaximin, and emerging resistance to front-line agents are evidence gaps underlying current recommendations. Methods: A randomized, double-blind trial was conducted in 4 countries (Afghanistan, Djibouti, Kenya, and Honduras) between September 2012 and July 2015...
September 23, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
17795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"